

|                             |                            |                 |           |
|-----------------------------|----------------------------|-----------------|-----------|
| Name of the Issuer:         | Invicta Diagnostic Limited | Last updated on | 13-Aug-25 |
| 1 Type of Issue (IPO / FPO) | IPO                        |                 |           |
| 2 Offer Size (Rs. Cr)*      | 28.12                      |                 |           |
| - Fresh Issue Size (Rs. Cr) | 28.12                      |                 |           |

\*Source: Prospectus dated December 04, 2025 and Final Post issue report dated December 10, 2025.

|   |                |
|---|----------------|
| 3 Grade of issue along with name of the rating agency |                |
| Name  | Not Applicable |
| Grade   | Not Applicable |

|   |       |
|---|-------|
| 4 Subscription Level (Number of times)                  | 6.46* |
| Source: Final Post issue report dated December 10, 2025 |       |
| *The above figure is after technical rejections         |       |

| 5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges   |               |             |   |   |        |  |       |  |               |   |               |  |               |
|---|---------------|-------------|---|---|--------|--|-------|--|---------------|---|---------------|--|---------------|
| <table border="1"> <thead> <tr> <th>Particulars</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>(i) allotment in the Offer <sup>(1)</sup></td> <td>10.60%</td> </tr> <tr> <td>(ii) at the end of 1st Quarter immediately after the listing</td> <td>0.00%</td> </tr> <tr> <td>(iii) at the end of 1st FY (March 31, 2026)*</td> <td>Not Available</td> </tr> <tr> <td>(iv) at the end of 2nd FY (March 31, 2027)*</td> <td>Not Available</td> </tr> <tr> <td>(v) at the end of 3rd FY (March 31, 2028)*</td> <td>Not Available</td> </tr> </tbody> </table> |               | Particulars | % | (i) allotment in the Offer <sup>(1)</sup> | 10.60% | (ii) at the end of 1st Quarter immediately after the listing | 0.00% | (iii) at the end of 1st FY (March 31, 2026)* | Not Available | (iv) at the end of 2nd FY (March 31, 2027)* | Not Available | (v) at the end of 3rd FY (March 31, 2028)* | Not Available |
| Particulars   | %             |             |   |   |        |  |       |  |               |   |               |  |               |
| (i) allotment in the Offer <sup>(1)</sup>   | 10.60%        |             |   |   |        |  |       |  |               |   |               |  |               |
| (ii) at the end of 1st Quarter immediately after the listing  | 0.00%         |             |   |   |        |  |       |  |               |   |               |  |               |
| (iii) at the end of 1st FY (March 31, 2026)*  | Not Available |             |   |   |        |  |       |  |               |   |               |  |               |
| (iv) at the end of 2nd FY (March 31, 2027)*   | Not Available |             |   |   |        |  |       |  |               |   |               |  |               |
| (v) at the end of 3rd FY (March 31, 2028)*  | Not Available |             |   |   |        |  |       |  |               |   |               |  |               |

\*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.

(1) Source: Basis of Allotment

|   |                             |                             |
|---|-----------------------------|-----------------------------|
| 6 Financials of the issuer (standalone) |                             | (In Rs. Lacs)               |
| Parameters                              | 1st FY<br>(March 31, 2026)* | 2nd FY<br>(March 31, 2027)* |
| Income from operations                  | Not Available               | Not Available               |
| Net Profit for the period               | Not Available               | Not Available               |
| Paid-up equity share capital            | Not Available               | Not Available               |
| Reserves excluding revaluation reserves | Not Available               | Not Available               |

\*Financials not disclosed as reporting for the relevant fiscal year has not been completed.

| 7 Trading Status in the scrip of the issuer  |               |             |        |  |               |   |               |  |               |
|--|---------------|-------------|--------|--|---------------|---|---------------|--|---------------|
| Company's Equity Shares are listed on National Stock Exchange of India Limited (NSE EMERGE)  |               |             |        |  |               |   |               |  |               |
| The Shares have not been suspended or delisted.  |               |             |        |  |               |   |               |  |               |
| <table border="1"> <thead> <tr> <th>Particulars</th> <th>Status</th> </tr> </thead> <tbody> <tr> <td>(i) at the end of 1st FY (March 31, 2026)*</td> <td>Not Available</td> </tr> <tr> <td>(ii) at the end of 2nd FY (March 31, 2027)*</td> <td>Not Available</td> </tr> <tr> <td>(iii) at the end of 3rd FY (March 31, 2028)*</td> <td>Not Available</td> </tr> </tbody> </table> |               | Particulars | Status | (i) at the end of 1st FY (March 31, 2026)* | Not Available | (ii) at the end of 2nd FY (March 31, 2027)* | Not Available | (iii) at the end of 3rd FY (March 31, 2028)* | Not Available |
| Particulars  | Status        |             |        |  |               |   |               |  |               |
| (i) at the end of 1st FY (March 31, 2026)*   | Not Available |             |        |  |               |   |               |  |               |
| (ii) at the end of 2nd FY (March 31, 2027)*  | Not Available |             |        |  |               |   |               |  |               |
| (iii) at the end of 3rd FY (March 31, 2028)*   | Not Available |             |        |  |               |   |               |  |               |
| *Trading status not disclosed as the relevant fiscal year has not been completed.  |               |             |        |  |               |   |               |  |               |

|  |                      |
|--|----------------------|
| 8 Change in Directors of issuer from the disclosures in the offer document |                      |
| Particulars  | Name of the Director |
| (i) at the end of 1st FY (March 31, 2026)*                                 | -                    |
| (ii) at the end of 2nd FY (March 31, 2027)*                                | -                    |
| (iii) at the end of 3rd FY (March 31, 2028)*                               | -                    |

Source: Stock Exchange Filings

\* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

**9 Status of implementation of project/ commencement of commercial production**

|   |                |
|---|----------------|
| (i) as disclosed in the offer document            | Not applicable |
| (ii) Actual implementation                        | Not applicable |
| (iii) Reasons for delay in implementation, if any | Not applicable |

**10 Status of utilization of offer proceeds**

|  |             |
|--|-------------|
| (i) as disclosed in the offer document | (Rs. Crore) |
| <b>Objects of the Fresh Issue</b>      |             |

| Objects of the Fresh Issue   | Amount       |
|--|--------------|
| Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; and | 21.11        |
| General corporate purposes#  | 4.07         |
| <b>Total</b>   | <b>25.18</b> |

Source: Prospectus dated December 04, 2025

|                                   |             |
|-----------------------------------|-------------|
| (ii) Actual utilization           | (Rs. Crore) |
| <b>Objects of the Fresh Issue</b> |             |

| Objects of the Fresh Issue   | Amount               |
|--|----------------------|
| Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; and | Not Available        |
| General Corporate Purpose  | Not Available        |
| <b>Total</b>   | <b>Not Available</b> |

|                                     |                |
|-------------------------------------|----------------|
| (iii) Reasons for deviation, if any | Not applicable |
|-------------------------------------|----------------|

**11 Comments of monitoring agency**

|  |               |
|--|---------------|
| (a) Comments on use of funds   | Not Available |
| (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document | Not Available |
| (c) Any other reservations expressed by the monitoring agency about the end use of funds                             | Not Available |

**12 Pricing Data**

|                            |           |
|----------------------------|-----------|
| Offer Price (Rs.):         | 85        |
| Designated Stock Exchange: | NSE       |
| Listing Date:              | 08-Dec-25 |

| Price parameters    | At close of listing day<br>(December 08, 2025) | At close of 30th calendar day from listing day<br>( January 07, 2025) <sup>(1)</sup> | At close of 90th calendar day from listing day<br>(February 06, 2025) <sup>(2)</sup> | As at the end of 1st FY after the listing of the issue<br>(March 31, 2026) |                         |                        |
|---------------------|--|--|--|--|-------------------------|------------------------|
|                     |  |  |  | Closing price  | High<br>(during the FY) | Low<br>(during the FY) |
| Market Price on NSE | 96.00  | Not Available  | Not Available  | Not Available  | Not Available           | Not Available          |
| NIFTY 50            | 25,960.55                                      | Not Available  | Not Available  | Not Available  | Not Available           | Not Available          |

| Price parameters    | As at the end of 2nd FY after the listing of the issue<br>(March 31, 2027) <sup>(3)(4)</sup> |                         |                        | As at the end of 3rd FY after the listing of the issue<br>(March 31, 2028) <sup>(3)(4)</sup> |                         |                        |
|---------------------|--|-------------------------|------------------------|--|-------------------------|------------------------|
|                     | Closing price  | High<br>(during the FY) | Low<br>(during the FY) | Closing price  | High<br>(during the FY) | Low<br>(during the FY) |
| Market Price on NSE | Not Available  | Not Available           | Not Available          | Not Available  | Not Available           | Not Available          |
| NIFTY 50            | Not Available  | Not Available           | Not Available          | Not Available  | Not Available           | Not Available          |

\*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed

(5) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Offer Price-

|                               |                                  | As disclosed in the offer document <sup>(1)</sup> | At the end of 1st FY (March 31, 2025) | At the end of 2nd FY (March 31, 2026) <sup>(2)</sup> | At the end of 3rd FY (March 31, 2027) <sup>(2)</sup> |
|-------------------------------|----------------------------------|---|---------------------------------------|--|--|
| Accounting ratio              | Issuer:                          | <b>5.86</b>                                       | <b>5.86</b>                           | Not Available  | Not Available  |
| EPS                           | Peer Group:                      |   |                                       |  |  |
|                               | Vijaya Diagnostic Centre Limited | 13.95   | 13.95                                 | Not Available  | Not Available  |
|                               | Krsnaa Diagnostics Limited       | 24.04   | 24.04                                 | Not Available  | Not Available  |
| Price to Earnings Ratio (P/E) | Issuer:                          | <b>14.51</b>                                      | <b>14.51</b>                          | Not Available  | Not Available  |
|                               | Peer Group:                      |   |                                       |  |  |
|                               | Vijaya Diagnostic Centre Limited | 72.22   | 72.22                                 | Not Available  | Not Available  |
|                               | Krsnaa Diagnostics Limited       | 34.39   | 34.39                                 | Not Available  | Not Available  |
| NAV                           | Issuer:                          | <b>16.15</b>                                      | <b>16.15</b>                          | Not Available  | Not Available  |
|                               | Peer Group:                      |   |                                       |  |  |
|                               | Vijaya Diagnostic Centre Limited | 77.86   | 77.86                                 | Not Available  | Not Available  |
|                               | Krsnaa Diagnostics Limited       | 272.54  | 272.54                                | Not Available  | Not Available  |
| RoNW(%)                       | Issuer:                          | <b>36.25%</b>                                     | <b>36.25%</b>                         | Not Available  | Not Available  |
|                               | Peer Group:                      |   |                                       |  |  |
|                               | Vijaya Diagnostic Centre Limited | 17.99%  | 17.99%                                | Not Available  | Not Available  |
|                               | Krsnaa Diagnostics Limited       | 8.79%   | 8.79%                                 | Not Available  | Not Available  |

**Notes:**

(1) Sourced from Prospectus dated December 04, 2025

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

14 Any other material information

| Date of disclosure to Designated Stock Exchange | Announcement   |
|---|----------------|
| Not Applicable                                  | Not Applicable |

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Socradamus Capital Private Limited ("Socradamus") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.